Foghorn Therapeutics Q2 2026 net loss narrows to $7.2M; cash runway into H1 2028

Foghorn Therapeutics Inc.

2026-Q2 EPS reported -$0.39 revenue$19,339,000

Net loss of $7.2M vs $17.9M in Q2 2025; collaboration revenue $16.1M (up from $7.6M) due to catch-up adjustment.
Cash, equivalents, and marketable securities $167.6M; runway into first half of 2028.
FHD-909 Phase 1 trial in SMARCA4-mutant NSCLC advancing; combination with anti-PD-1 shows complete tumor regression in preclinical models.
Selective EP300 degrader program targeting IND in 2027 for multiple myeloma and DLBCL; preclinical data outperforms clinical benchmark.
CBPd-171 timeline delayed due to operational issue at third-party CRO; updated guidance pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.